Retatrutide

Retatrutide (LY3437943) is a single investigational molecule designed to engage three nutrient-responsive hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Published phase 2 research evaluated dose-response, safety, and metabolic outcomes in adults with obesity, while phase 3 programs continue to examine obesity, type 2 diabetes, cardiovascular and kidney outcomes, sleep apnea, and related conditions. This compound is presented retatrutide as an investigational compound and should not imply that a research vial is equivalent to a clinical-trial product.